C9097 — Inj, faricimab-svoa, 0.1 mg
C9097 is a HCPCS Level II code for inj, faricimab-svoa, 0.1 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on September 30, 2022 and is not valid on new claims.
This code has been terminated
CMS terminated C9097 on September 30, 2022. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9097
- Long descriptor
- Inj, faricimab-svoa, 0.1 mg
- Short descriptor
- Inj, faricimab-svoa, 0.1 mg
- Added
- July 1, 2022
- Terminated
- September 30, 2022
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9097
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9097 is not quite right, the correct code is very often within a few positions of it.
- C9089Bupivacaine, collagen-matrix implant, 1 mgterminated
- C9090Injection, plasminogen, human-tvmh, 1 mgterminated
- C9091Injection, sirolimus protein-bound particles, 1 mgterminated
- C9092Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mgterminated
- C9093Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mgterminated
- C9094Inj, sutimlimab-jome, 10 mgterminated
- C9095Inj, tebentafusp-tebn, 1 mcgterminated
- C9096Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgramterminated
- C9098Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9101Injection, oliceridine, 0.1 mg
- C9113Injection, pantoprazole sodium, per vialterminated
- C9121Injection, argatroban, per 5 mgterminated
- C9122Mometasone furoate sinus implant, 10 micrograms (sinuva)terminated
- C9132Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activityterminated
- C9133Factor ix (antihemophilic factor, recombinant), rixubis, per i.u.terminated
- C9134Factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.terminated
Questions about C9097
What is HCPCS code C9097?
C9097 is a HCPCS Level II code for inj, faricimab-svoa, 0.1 mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9097?
The CMS HCPCS file marks C9097 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is C9097 still valid?
No. C9097 was terminated on September 30, 2022 and should not be used on new claims.